• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CEO CORNER
    • SCIENTIFIC ADVISORY BOARD
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
  • CONTACT US

The CEO Corner is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.


October 15, 2026

August 4, 2026

June 4, 2026

March 13, 2026

January 9, 2026

November 25, 2025

Footer

FOLLOW US

X
LINKEDIN
Youtube
Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.